Search Tag: Oncology
2026 31 Mar
Spiculated breast lesions represent a recognised mammographic presentation and are strongly associated with malignancy. Spiculation is frequently observed in low-grade tumours and is often linked with favourable tumour characteristics, including oestrogen receptor positivity and lower histological grade. However, spicules may also be present 1Read more
2026 31 Mar
Spiculated breast lesions represent a recognised mammographic presentation and are strongly associated with malignancy. Spiculation is frequently observed in low-grade tumours and is often linked with favourable tumour characteristics, including oestrogen receptor positivity and lower histological grade. However, spicules may also be present 1Read more
2026 31 Mar
Accurate preoperative evaluation of the nipple–areola complex (NAC) is essential for surgical planning in breast cancer, as its involvement may preclude nipple-sparing procedures. Imaging plays a central role in identifying infiltration and guiding clinical decisions. Magnetic resonance imaging (MRI) is widely used for this purpose, while contra1Read more
2026 31 Mar
Accurate preoperative evaluation of the nipple–areola complex (NAC) is essential for surgical planning in breast cancer, as its involvement may preclude nipple-sparing procedures. Imaging plays a central role in identifying infiltration and guiding clinical decisions. Magnetic resonance imaging (MRI) is widely used for this purpose, while contra1Read more
2026 04 Feb
Multiphase contrast-enhanced CT (CECT) is widely used to evaluate renal tumours, yet several treatment-relevant factors remain difficult to determine before surgery. Histological subtype, clinical stage and anatomical complexity can influence surgical planning and clinical decision-making, but these elements are not always straightforward to 1Read more
2026 04 Feb
Multiphase contrast-enhanced CT (CECT) is widely used to evaluate renal tumours, yet several treatment-relevant factors remain difficult to determine before surgery. Histological subtype, clinical stage and anatomical complexity can influence surgical planning and clinical decision-making, but these elements are not always straightforward to 1Read more
2025 09 Nov
Prostate-specific membrane antigen PET/CT using fluorine-18 PSMA-1007 is being used to stage prostate cancer before treatment. Beyond image quality, the tracer’s practical features support routine deployment and may help visualise pelvic disease. A systematic review and metaanalysis pooled results from clinical studies that compared imaging d1Read more
2025 16 May
Accurate identification of epidermal growth factor receptor (EGFR) mutations plays a central role in guiding targeted treatment decisions for patients with lung adenocarcinoma. Current clinical methods for EGFR status detection, including tissue and liquid biopsies, present several limitations. Tissue biopsies are invasive, may not be feasibl1Read more
2024 25 Apr
Tissue ablation techniques are increasingly important in medical interventions, offering minimally invasive options for treating focal malignancies. These procedures, guided by precise imaging, reduce morbidity and mortality compared to surgical resections. They include energy-based methods like high-intensity focused ultrasound (HIFU) and no1Read more
2024 21 Mar
Flamingo Therapeutics announced the appointment of Ezra Cohen, MD to its Board of Directors. Dr. Cohen is a leading medical oncologist and cancer researcher who brings unique and relevant expertise in the development of drugs, especially head and neck cancer, to the Flamingo board. “Ezra is a recognized leader in oncology drug deve1Read more
2024 03 Feb
As we approach World Cancer Day, the University of Liverpool announces its appointment of a new Chair of Oncology to tackle cancer in the Liverpool City Region. Professor Tim Maughan – whose appointment includes an honorary contract with The Clatterbridge Cancer Centre NHS Foundation Trust – takes on this newly created role to work wi1Read more
2024 22 Jan
Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will serve on the Pharmaceuticals Executive Committee and be based in Berlin, Germany. Gerd Kruege1Read more
2024 22 Mar
<marquee behavior="slide" direction="left" scrollamount="30"><h2 style="text-align: center;"><font color="#000099"><b> Find ESMO On Social Media </b> </font></h2><div style="text-align: center;"><a href=https://www.twitter.com/myesmo target="_blank"><img src="/uploads/twnew.png" style="text-align: initial;" width=65 height=65></Read more
2024 29 Feb
<marquee behavior="slide" direction="left" scrollamount="30" style="text-align: center;> Find BIR on Social Media </marquee> Read more
2023 25 Sep
Experienced healthcare leader brings 25 years of expertise in real-world data, analytics, and strategic planning Ontada ® , a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, announced the appointment of Christine Davis as its new president. In this role, Davis 1Read more
2023 07 Sep
Located in Warsaw, the capital of Poland, the Maria Skłodowska-Curie National Research Institute of Oncology is a leading centre for cancer research and treatment with over 85 years of distinguished tradition. A beacon of modern oncological care, the centre comprises 13 highly specialised departments, each dedicated to providing the highest level 1Read more
2023 07 Sep
Located in Warsaw, the capital of Poland, the Maria Skłodowska-Curie National Research Institute of Oncology is a leading centre for cancer research and treatment with over 85 years of distinguished tradition. A beacon of modern oncological care, the centre comprises 13 highly specialised departments, each dedicated to providing the highest level 1Read more
2023 22 Aug
CureMD, a leading provider of comprehensive technology solutions for community oncology, is proud to announce its partnership with Tempus, a leader in artificial intelligence and precision medicine, to integrate Tempus’ advanced genomic testing capabilities into CureMD’s cutting-edge Electronic Health Record (EHR) system. "We are excited to 1Read more
2022 04 Oct
Kineta, Inc, a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology announced the appointment of Keith Baker as the Company’s new Chief Financial Officer (CFO). “It is a pleasure to welcome Keith to our management team at this pivotal time for Kineta,” said Shawn Iadonato, Ph.D., Chief Executive 1Read more